Dr. Yi Ren is currently General Manager of Nanjing Medichem Biopharmaceutical Development Co., as well as General Manager and board of director of Chizhou Ruick Pharmaceutical Co. From October 2008 to March 2013, Dr. Ren was senior director and head of CMC at Roche R&D China Ltd. in Shanghai. Dr. Ren was also core leadership team member of 5 different Roche global organizations including API, formulation, small molecule R&D, virology R&D, and China R&D. From August 1998 to October 2008, Dr. Ren was in Roche US as Research Leader in Chemical Synthesis Dept.
Dr. Ren has extensive experience in R&D, manufacturing, and commercialization of both generic drugs as well as innovative pharmaceuticals. Dr. Ren is a co-inventor of Zelboraf, a novel treatment of malignant melanoma.
Dr. Ren obtained his PhD. degree in Organic Chemistry from the University of Toronto; a postdoctoral training at the University of Michigan. Dr. Ren also holds an MBA degree from Rutgers University in the United States.